Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap

Cornelia Geisler Crone; Jannik Helweg-Larsen; Morten Steensen; Maiken Cavling Arendrup; Marie Helleberg

doi:10.1016/j.mycmed.2021.101228

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap

Cornelia Geisler Crone^*, Jannik Helweg-Larsen, Morten Steensen, Maiken Cavling Arendrup, Marie Helleberg

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

7 Citations (Scopus)

15 Downloads (Pure)

Abstract

Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.

Original language	English
Article number	101228
Journal	Journal of Medical Mycology
Volume	32
Issue number	1
ISSN	1156-5233
DOIs	https://doi.org/10.1016/j.mycmed.2021.101228
Publication status	Published - 2022

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

Keywords

COVID-19
Immunosuppression
Invasive fungal infection
Mucormycosis
Rhizopus microsporum
SARS-COV-2

Access to Document

10.1016/j.mycmed.2021.101228Licence: CC BY

FulltextFinal published version, 890 KBLicence: CC BY

Cite this

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient : Mind the diagnostic gap. / Crone, Cornelia Geisler; Helweg-Larsen, Jannik; Steensen, Morten; Arendrup, Maiken Cavling; Helleberg, Marie.

In: Journal of Medical Mycology, Vol. 32, No. 1, 101228, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{a552b86426ed4d6a8559f58696008b78,

title = "Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap",

abstract = "Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.",

keywords = "COVID-19, Immunosuppression, Invasive fungal infection, Mucormycosis, Rhizopus microsporum, SARS-COV-2",

author = "Crone, {Cornelia Geisler} and Jannik Helweg-Larsen and Morten Steensen and Arendrup, {Maiken Cavling} and Marie Helleberg",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2022",

doi = "10.1016/j.mycmed.2021.101228",

language = "English",

volume = "32",

journal = "Journal de Mycologie Medicale",

issn = "1156-5233",

publisher = "Elsevier Masson",

number = "1",

}

TY - JOUR

T1 - Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient

T2 - Mind the diagnostic gap

AU - Crone, Cornelia Geisler

AU - Helweg-Larsen, Jannik

AU - Steensen, Morten

AU - Arendrup, Maiken Cavling

AU - Helleberg, Marie

PY - 2022

Y1 - 2022

N2 - Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.

AB - Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.

KW - COVID-19

KW - Immunosuppression

KW - Invasive fungal infection

KW - Mucormycosis

KW - Rhizopus microsporum

KW - SARS-COV-2

U2 - 10.1016/j.mycmed.2021.101228

DO - 10.1016/j.mycmed.2021.101228

M3 - Journal article

C2 - 34826672

AN - SCOPUS:85119479277

VL - 32

JO - Journal de Mycologie Medicale

JF - Journal de Mycologie Medicale

SN - 1156-5233

IS - 1

M1 - 101228

ER -